Literature DB >> 26019016

Factors Responsible for Plasma β-Amyloid Accumulation in Chronic Kidney Disease.

Janine Gronewold1, Hans-Wolfgang Klafki2,3, Enrico Baldelli1, Britta Kaltwasser1, Ulla K Seidel1, Olga Todica1, Michaela Volsek4, Ute Haußmann2, Jens Wiltfang3, Andreas Kribben4, Heike Bruck4, Dirk M Hermann5.   

Abstract

Disturbed brain-to-blood elimination of β-amyloid (Aβ) promotes cerebral Aβ accumulation in Alzheimer's disease. Considering that the kidneys are involved in Aβ elimination from the blood, we evaluated how chronic kidney disease (CKD) affects plasma Aβ. In 106 CKD patients stages 3-5 (including 19 patients on hemodialysis and 15 kidney recipients), 53 control subjects with comparable vascular risk profile and 10 kidney donors, plasma Aβ was determined using electrochemiluminescence immunoassay and gel electrophoresis followed by Western blotting. Plasma Aβ increased with CKD stage (control = 182.98 ± 76.73 pg/ml; CKD3A = 248.34 ± 103.77 pg/ml; CKD3B = 259.25 ± 97.74 pg/ml; CKD4 = 489.16 ± 154.16 pg/ml; CKD5 = 721.19 ± 291.69 pg/ml) and was not influenced by hemodialysis (CKD5D = 697.97 ± 265.91 pg/ml). Renal transplantation reduced plasma Aβ (332.57 ± 162.82 pg/ml), whereas kidney donation increased it (251.51 ± 34.34 pg/ml). Gel electrophoresis confirmed stage-dependent elevation namely of Aβ1-40, the most abundant Aβ peptide. In a multivariable regression including age, sex, estimated glomerular filtration rate (eGFR), potassium, hemoglobin, urine urea, and urine total protein, the factors eGFR (β = -0.42, p < 0.001), hemoglobin (β = -0.17, p = 0.020), and urine protein (β = 0.26, p = 0.008) were associated with plasma Aβ. In a regression including age, sex, eGFR, potassium, hemoglobin and the vascular risk factors systolic blood pressure, smoking, LDL, HDL, HbA1c, body mass index, brain-derived natriuretic peptide and fibrinogen, the factors eGFR (β = -0.53, p < 0.001), body mass index (β = -0.17, p = 0.022), and fibrinogen (β = 0.18, p = 0.024) were associated with plasma Aβ. Our results demonstrate a stage-dependent plasma Aβ increase that is augmented by loss of glomerulotubular integrity, low body weight, and inflammation, demonstrating a multifaceted role of renal dysfunction in Aβ retention.

Entities:  

Keywords:  Alzheimer’s disease; Chronic kidney disease; Neurovascular hypothesis; Peripheral sink hypothesis; Plasma β-amyloid; Vascular risk factor

Mesh:

Substances:

Year:  2015        PMID: 26019016     DOI: 10.1007/s12035-015-9218-y

Source DB:  PubMed          Journal:  Mol Neurobiol        ISSN: 0893-7648            Impact factor:   5.590


  23 in total

1.  K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification.

Authors: 
Journal:  Am J Kidney Dis       Date:  2002-02       Impact factor: 8.860

Review 2.  Neurovascular mechanisms of Alzheimer's neurodegeneration.

Authors:  Berislav V Zlokovic
Journal:  Trends Neurosci       Date:  2005-04       Impact factor: 13.837

Review 3.  The blood-brain barrier in health and chronic neurodegenerative disorders.

Authors:  Berislav V Zlokovic
Journal:  Neuron       Date:  2008-01-24       Impact factor: 17.173

Review 4.  Obesity in CKD--what should nephrologists know?

Authors:  Peter Stenvinkel; Carmine Zoccali; T Alp Ikizler
Journal:  J Am Soc Nephrol       Date:  2013-10-10       Impact factor: 10.121

5.  Association Between Serum Amyloid-Beta and Renal Functions: Implications for Roles of Kidney in Amyloid-Beta Clearance.

Authors:  Yu-Hui Liu; Yang Xiang; Ye-Ran Wang; Shu-Sheng Jiao; Qing-Hua Wang; Xian-Le Bu; Chi Zhu; Xiu-Qing Yao; Brian Giunta; Jun Tan; Hua-Dong Zhou; Yan-Jiang Wang
Journal:  Mol Neurobiol       Date:  2014-08-14       Impact factor: 5.590

6.  Relationship between magnesium and clinical biomarkers on inhibition of vascular calcification.

Authors:  Silvia Salem; Heike Bruck; Ferdinand H Bahlmann; Mirjam Peter; Jutta Passlick-Deetjen; Axel Kretschmer; Sonja Steppan; Michaela Volsek; Andreas Kribben; Marc Nierhaus; Vera Jankowski; Walter Zidek; Joachim Jankowski
Journal:  Am J Nephrol       Date:  2011-12-15       Impact factor: 3.754

Review 7.  Vascular cognitive impairment: current concepts and clinical developments.

Authors:  Paige Moorhouse; Kenneth Rockwood
Journal:  Lancet Neurol       Date:  2008-03       Impact factor: 44.182

Review 8.  Clearance of amyloid-beta in Alzheimer's disease: shifting the action site from center to periphery.

Authors:  Yu-Hui Liu; Ye-Ran Wang; Yang Xiang; Hua-Dong Zhou; Brian Giunta; Noralyn B Mañucat-Tan; Jun Tan; Xin-Fu Zhou; Yan-Jiang Wang
Journal:  Mol Neurobiol       Date:  2014-04-15       Impact factor: 5.590

9.  Serum creatinine levels correlate with plasma amyloid Beta protein.

Authors:  Zoe Arvanitakis; John A Lucas; Linda H Younkin; Steven G Younkin; Neill R Graff-Radford
Journal:  Alzheimer Dis Assoc Disord       Date:  2002 Jul-Sep       Impact factor: 2.703

10.  A novel Aβ-fibrinogen interaction inhibitor rescues altered thrombosis and cognitive decline in Alzheimer's disease mice.

Authors:  Hyung Jin Ahn; J Fraser Glickman; Ka Lai Poon; Daria Zamolodchikov; Odella C Jno-Charles; Erin H Norris; Sidney Strickland
Journal:  J Exp Med       Date:  2014-05-12       Impact factor: 14.307

View more
  10 in total

Review 1.  [New biomarkers for Alzheimer's disease in cerebrospinal fluid and blood].

Authors:  Jonathan Vogelgsang; Jens Wiltfang
Journal:  Nervenarzt       Date:  2019-09       Impact factor: 1.214

2.  Multiplex immunoassay measurement of amyloid-β42 to amyloid-β40 ratio in plasma discriminates between dementia due to Alzheimer's disease and dementia not due to Alzheimer's disease.

Authors:  Jonathan Vogelgsang; Hedieh Shahpasand-Kroner; Rebekka Vogelgsang; Frank Streit; Ruth Vukovich; Jens Wiltfang
Journal:  Exp Brain Res       Date:  2018-02-26       Impact factor: 1.972

3.  Cognitive Performance Is Highly Stable over a 2-Year-Follow-Up in Chronic Kidney Disease Patients in a Dedicated Medical Environment.

Authors:  Janine Gronewold; Olga Todica; Ulla K Seidel; Michaela Volsek; Andreas Kribben; Heike Bruck; Dirk M Hermann
Journal:  PLoS One       Date:  2016-11-11       Impact factor: 3.240

4.  Whole exome sequence-based association analyses of plasma amyloid-β in African and European Americans; the Atherosclerosis Risk in Communities-Neurocognitive Study.

Authors:  Jeannette Simino; Zhiying Wang; Jan Bressler; Vincent Chouraki; Qiong Yang; Steven G Younkin; Sudha Seshadri; Myriam Fornage; Eric Boerwinkle; Thomas H Mosley
Journal:  PLoS One       Date:  2017-07-13       Impact factor: 3.240

5.  Abnormal amyloid β42 expression and increased oxidative stress in plasma of CKD patients with cognitive dysfunction: A small scale case control study comparison with Alzheimer's disease.

Authors:  G Vinothkumar; C Kedharnath; S Krishnakumar; S Sreedhar; K Preethikrishnan; S Dinesh; A Sundaram; D Balakrishnan; G Shivashekar; P Venkataraman
Journal:  BBA Clin       Date:  2017-06-23

6.  Blood-based systems biology biomarkers for next-generation clinical trials in Alzheimer's disease
.

Authors:  Harald Hampel; Andrea Vergallo; Mohammad Afshar; Leyla Akman-Anderson; Joaquín Arenas; Norbert Benda; Richard Batrla; Karl Broich; Filippo Caraci; A Claudio Cuello; Enzo Emanuele; Marion Haberkamp; Steven J Kiddle; Alejandro Lucía; Mark Mapstone; Steven R Verdooner; Janet Woodcock; Simone Lista
Journal:  Dialogues Clin Neurosci       Date:  2019       Impact factor: 5.986

7.  Relationship of amyloid-β1-42 in blood and brain amyloid: Ginkgo Evaluation of Memory Study.

Authors:  Oscar L Lopez; William E Klunk; Chester A Mathis; Beth E Snitz; Yuefang Chang; Russell P Tracy; Lewis H Kuller
Journal:  Brain Commun       Date:  2019-11-27

Review 8.  Based on molecular structures: Amyloid-β generation, clearance, toxicity and therapeutic strategies.

Authors:  Hai Yang; Jinping Li; Xiaoxiong Li; Linqiu Ma; Mingliang Hou; Huadong Zhou; Rui Zhou
Journal:  Front Mol Neurosci       Date:  2022-08-31       Impact factor: 6.261

9.  Common Impact of Chronic Kidney Disease and Brain Microhemorrhages on Cerebral Aβ Pathology in SHRSP.

Authors:  Daniel Pirici; Luiza Stanaszek; Cornelia Garz; Solveig Niklass; Hans-Jochen Heinze; Thomas Kalinski; Johannes Attems; Stefanie Schreiber
Journal:  Brain Pathol       Date:  2016-05-30       Impact factor: 6.508

Review 10.  Diabetes, Albuminuria and the Kidney-Brain Axis.

Authors:  Diana Maria Ariton; Joan Jiménez-Balado; Olga Maisterra; Francesc Pujadas; María José Soler; Pilar Delgado
Journal:  J Clin Med       Date:  2021-05-27       Impact factor: 4.241

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.